Metastasis to bone: Causes, consequences and therapeutic opportunities

Nature Reviews Cancer

Volumn 2, Issue 8, 2002, Pages 584-593

  Mundy, Gregory R ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; HORMONE ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR FC; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; CALCIUM; CARRIER PROTEIN; CELL RECEPTOR; GLYCOPROTEIN; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; VITAMIN D;

BONE METASTASIS; BREAST CANCER; CANCER PAIN; CARCINOGENESIS; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; HUMAN; LUNG CANCER; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT PLANNING; BONE TUMOR; BREAST TUMOR; FEMALE; LUNG TUMOR; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

BONE NEOPLASMS; BREAST NEOPLASMS; CALCIUM; CARRIER PROTEINS; DIPHOSPHONATES; FEMALE; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; VITAMIN D;

EID: 0036675220     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc867     Document Type: Review

References (76)

1. Wingo, P. A., Tong, T. & Bolden, S. Cancer statistics. Cancer J. Clin. 45, 8-30 (1995).
2. Mantyh, P. W., Clohisy, D. R., Kotzenburg, M. & Hunt, S. P. Molecular mechanisms of cancer pain. Nature Rev. Cancer 2, 201-209 (2000).
3. Honore, P. et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Med. 6, 521-528 (2000). Evidence that the bone-resorption inhibitor osteoprotegerin inhibits not just osteolysis but also bone pain in metastatic bone disease.
4. Boyde, A., Maconnachie, E., Reid, S. A., Delling, G. & Mundy, G. R. Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan. Electron Microsc. 4, 1537-1554 (1986). This paper shows, by scanning electron microscopy, evidence of osteoclastic resorption pits at bone metastatic sites, indicating the importance of osteoclasts as cellular mediators of osteolysis.
5. Stewart, A. F. et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J. Clin. Endocrinol. Metab. 55, 219-227 (1982). Histomorphometric evidence of the abnormalities in osteoblastic and osteolytic activity that occurs in patients with bone metastases. This was shown by observing the impaired osteoblastic response to increased osteoclastic resorption.
6. Charhon, S. A. et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51, 918-924 (1983).
7. Garnero, P. et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 82, 858-864 (2000).
8. Koga, H. et al. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39, 1-7 (1999).
9. Koizumi, M. et al. Dissociation of bone formation markers in bone metastasis of prostate cancer. Br. J. Cancer 75, 1601-1604 (1997).
10. Percival, R. C. et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur. J. Surg. Oncol. 13, 41-49 (1987). One of the first studies to indicate that osteoblastic metastases are accompanied by increased bone resorption in patients with prostate cancer.
11. Yoshida, K. et al. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer 80, 1760-1767 (1997).
12. Pelger, R. C., Hamdy, N. A., Zwinderman, A. H., Lycklama a Nijeholt, A. A. & Papapoulos, S. E. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 22, 403-408 (1998).
13. Yi, B. et al. PDGF in breast cancer promotes osteosclerotic bone metastases. J. Bone Min. Res. 15 (Suppl 1) A1035 (2000).
14. Adami, S. Bisphosphonates in prostate carcinoma. Cancer 80, 1674-1679 (1997).
15. Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature 411, 375-379 (2001). An excellent review that cites evidence for the importance of the stroma in cancer-cell behaviour at primary and metastatic sites.
16. Liotta, L. A. & Kohn, E. Cancer invasion and metastases. JAMA 263, 1123-1126 (1990).
17. Fidler, I. J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 38, 2651-2660 (1978).
18. Zetter, B. R. The cellular basis of site-specific tumor metastasis. N. Engl. J. Med. 322, 605-812 (1990).
19. Southby, J. et al. Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res. 50, 7710-7716 (1990).
20. Powell, G. J. et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res. 51, 3059-3061 (1991). Clinical data that shows evidence for increased PTHrP expression in bone metastatic sites in patients with breast cancer.
21. Bryden, A. A., Hoyland, J. A., Freemont, A. J., Clarke, N. W. & George, N. J. Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br. J. Cancer 86, 322-325 (2002).
22. Miki, T., Yano, S., Hanibuchi, M. & Sone, S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol. Res. 12, 209-217 (2001).
23. Henderson, M. et al. Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J. Natl Cancer Inst. 93, 234-237 (2001).
24. Guise, T. A. et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast-cancer-mediated osteolysis. J. Clin. Invest. 98, 1544-1549 (1996). Human breast cancer cells, when inoculated into the systemic circulation of nude mice, cause osteolytic lesions that are abrogated by neutralizing antibodies to the tumour peptide PTHrP.
25. Stewart, A. F. PTHrP (1-36) as a skeletal anabolic agent for the treatment of osteoporosis. Bone 19, 303-306 (1996).
26. Zhang, Q. X., Borg, A., Wolf, D. M., Oesterreich, S. & Fuqua, S. A. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 57, 1244-1249 (1997).
27. De Larco, J. E. et al. A potential role for IL-8 in the metastatic phenotype of breast carcinoma cells. Am. J. Pathol. 158, 639-646 (2001).
28. Downey, S. E. et al. Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue. J. Pathol. 183, 212-217 (1997).
29. Gallwitz, W. E. et al. Low doses of 6-thioguanine and 6-mercaptoguanosine inhibit osteolytic bone disease caused by human breast cancer. J. Bone Min. Res. 15 (Suppl. 1), S200 (2000).
30. Ogata, E. PTHrP, paraneoplastic syndrome and cancer metastasis. J. Bone Min. Metab, 19 (Suppl. 1), S1-S2 (2001).
31. Zhang, J. et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107, 1235-1244 (2001).
32. Nelson, J. B. et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med. 1, 944-949 (1995).
33. Yin, J. J. et al. Endothelin A receptor blockade inhibits osteoblastic metastases. J. Bone Min. Res. 15 (Suppl. 1), 1254 (2000).
34. Yin, J. J. et al. Osteoblastic bone metastases: tumor-produced endothelin-1 mediates new bone formation via the endothelin A receptor. J. Back Musculoskeletal. Rehabil. 14 (Suppl. 1), F400 (1999). Data confirming the molecular mechanisms that are responsible for the 'vicious cycle' in breast cancer metastasis to bone.
35. Marcelli, M. et al. A single nucleotide substitution introduces a premature termination codon into the androgen receptor gene of a patient with receptor-negative androgen resistance. J. Clin. Invest. 85, 1522-1528 (1990).
36. Marquardt, H., Lioubin, M. N. & Ikeda, T. Complete amino acid sequence of human transforming growth factor type-β2. J. Biol. Chem. 262, 12127-12130 (1997).
37. Harris, S. E. et al. Effects of transforming growth factor-β on bone nodule formation and expression of bone morphogenic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type 1 collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J. Bone Min. Res. 9, 855-863 (1994).
38. Rabbani, S. A. et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem. Biophys. Res. Commun. 173, 1058-1064 (1990).
39. Achbarou, A. et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 54, 2372-2377 (1994).
40. Rabbani, S. A. et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J. Biol. Chem. 267, 14151-14156 (1992).
41. Dallas, S. L. et al. Characterization and autoregulation of latent TGF-β complexes in osteoblast-like cell lines: production of a latent complex lacking the latent TGF-β-binding protein (LTBP). J. Biol. Chem. 269, 6815-6822 (1994).
42. Dallas, S. L. et al. Dual role for the latent transforming growth actor-β binding protein in storage of latent TGF-β in the extracellular matrix and as a structural matrix protein. J. Cell Biol. 131, 539-549 (1995).
43. Cramer, S. D., Chen, Z. & Peehl, D. M. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP stimulated cAMP accumulation in mouse osteoblasts. J. Urol. 156, 526-531 (1996).
44. Iwamura, M., Hellman, J., Cockett, A. T., Lilja, H. & Gershagen, S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48, 317-325 (1996).
45. Matuo, Y. et al. Heparin binding affinity of rat prostate growth factor in normal and cancerous prostate: partial purification and characterization of rat prostate growth factor in the Dunning tumor. Cancer Res. 47, 188-192 (1987).
46. Mansson, P. E. et al. HBGF1 gene expression in normal rat prostate and two transplantable rat prostate tumors. Cancer Res. 49, 2485-2494 (1989).
47. Canalis, E. et al. Effects of endothelial cell growth factor on bone remodeling in vitro. J. Clin. Invest. 79, 52-58 (1987).
48. Canalis, E., Centrella, M. & McCarthy, T. Effects of basic fibroblast growth factor on bone formation in vitro. J. Clin. Invest. 81, 1572-1577 (1988).
49. Mayahara, H. et al. In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 9, 73-80 (1993)
50. Dunstan, C. R. et al. Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J. Bone Min. Res. 14, 953-959 (1999).
51. Izbicka, E. et al. Human amniotic tumor which induces new bone formation in vivo produces a growth regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor (bFGF). Cancer Res. 56, 633-636 (1996).
52. Yi, B., Williams, P. J., Niewolna, M., Wang, Y. & Yoneda, T. Tumor-derived PDGF-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res. 62, 917-923 (2002).
53. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571-573 (1889). The classical paper describing the 'seed and soil' hypothesis of tumour-cell metastasis.
54. Yin, J. J. et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206 (1999).
55. Hiraga, T., Williams, P. J., Mundy, G. R. & Yoneda, T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 61, 4418-4424 (2001).
56. Rasmussen, A. A. & Cullen, K. J. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res. Treat. 47, 219-233 (1998).
57. Yu, H. & Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst. 92, 1472-1489 (2000).
58. Sasaki, A. et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55, 3551-3557 (1995). In a preclinical model of human breast cancer metastasis to bone, bisphosphonates reduce not only osteolysis but also tumour burden.
59. Diel, I. J. et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339, 357-363 (1998). The authors show, in a controversial study, that the bisphosphonate clodronate reduces tumour burden in both bone and non-bone metastatic sites in patients with breast cancer.
60. Powles, T. J. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 91, 730 (1999).
61. Saarto, T., Blomqvist, C., Virkkunen, P. & Elomaa, I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J. Clin. Oncol. 19, 10-17 (2001).
62. Griepp, P. et al. A single subcutaneous dose of an osteoprotegerin (OPG) construct (AMGN-0007) causes a profound and sustained decrease of bone resorption comparable to standard intravenous bisphosphonate in patients with multiple myeloma. Blood 92 (Suppl. 1), A3227 (1998).
63. Oyajobi, B. O. et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor-κB-IgG-Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 61, 2572-2578 (2001).
64. Kuehl, W. M. & Bergsagel, P. L. Multiple myeloma: evolving genetic events and host interactions. Nature Rev. Cancer 2, 175-187 (2002).
65. Seyberth, H. W. et al. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N. Engl. J. Med. 293, 1278-1283 (1975).
66. Lee, M. V., Fong, E. M., Singer, F. R. & Guenette, R. S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61, 2602-2608 (2001).
67. Sanders, J. L. et al. Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 141, 4357-4364 (2000).
68. 2+-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells. Am. J. Physiol. Endocrinol. Metab. 281, E1267-E1274 (2001).
69. Moseley, J. M. et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc. Natl Acad. Sci. USA 84, 5048-5052 (1987).
70. Stewart, A. F., Wu, T., Goumas, D., Burtis, W. J. & Broadus, A. E. N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: identification of parathyroid hormone-like and parathyroid hormone-unlike domains. Biochem. Biophys. Res. Commun. 146, 672-678 (1987).
71. Strewler, G. J. et al. N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase stimulating proteins: idenfication of parathyroid hormone-unlike domains. Biochem. Biophys. Res. Commun. 146, 672-678 (1987).
72. Yates, A. J. P. et al. Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption and bone metabolism. J. Clin. Invest. 81, 932 (1988).
73. Mundy, G. R. Calcium Homeostasis: Hypercalcemia and Hypocalcemia 2nd edn (Martin Dunitz, London, 1990).
74. Mundy, G. R., Wilkinson, R. & Heath, D. A. Comparative study of available medical therapy for hypercalcemia of malignancy. Am. J. Med. 74, 421-432 (1983).
75. Silverman, I. E. & Flynn, J. A. Images in clinical medicine. Ivory vertebra. N. Engl. J. Med. 338, 100 (1998).
76. Fidler, I. J. Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl Cancer Inst. 87, 1588-1592 (1995).